Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 4Gastrointestinal 3Genitourinary 2Dermatologic 2

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × tesetaxel × Genitourinary × Clear all
NCT01296243 2012-07-24

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Genta Incorporated

Phase 2 Unknown
57 enrolled
Genitourinary

Prostatic Neoplasms

NCT01215877 2012-07-11

Tesetaxel for Previously Treated Patients With Bladder Cancer

Genta Incorporated

Phase 2 Unknown
33 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡